Research published today (Jan. 22) in the journal Brain reveals a new approach to Alzheimer’s disease (AD) that may eventually make it possible to reverse memory loss, a hallmark of the disease in its late stages.
The team, led by University at Buffalo scientists, found that by focusing on gene changes caused by influences other than DNA sequences — called epigenetics — it was possible to reverse memory decline in an animal model of AD.
“In this paper, we have not only identified the epigenetic factors that contribute to the memory loss, we also found ways to temporarily reverse them in an animal model of AD,” said senior author Zhen Yan, PhD, a SUNY Distinguished Professor in the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.
The research was conducted on mouse models carrying gene mutations for familial AD — where more than one member of a family has the disease — and on post-mortem brain tissues from AD patients.
AD is linked to epigenetic abnormality
AD results from both genetic and environmental risk factors, such as aging, which combine to result in epigenetic changes, leading to gene expression changes, but little is known about how that occurs.
The epigenetic changes in AD happen primarily in the later stages, when patients are unable to retain recently learned information and exhibit the most dramatic cognitive decline, Yan said. A key reason for the cognitive decline is the loss of glutamate receptors, which are critical to learning and short-term memory.
“We found that in Alzheimer’s disease, many subunits of glutamate receptors in the frontal cortex are downregulated, disrupting the excitatory signals, which impairs working memory,” Yan said.
The researchers found that the loss of glutamate receptors is the result of an epigenetic process known as repressive histone modification, which is elevated in AD. They saw this both in the animal models they studied and in post-mortem tissue of AD patients.
Yan explained that histone modifiers change the structure of chromatin, which controls how genetic material gains access to a cell’s transcriptional machinery.
“This AD-linked abnormal histone modification is what represses gene expression, diminishing glutamate receptors, which leads to loss of synaptic function and memory deficits,” Yan said.
Potential drug targets
Understanding that process has revealed potential drug targets, she said, since repressive histone modification is controlled or catalyzed by enzymes.
“Our study not only reveals the correlation between epigenetic changes and AD, we also found we can correct the cognitive dysfunction by targeting the epigenetic enzymes to restore glutamate receptors,” Yan said.
The AD animals were injected three times with compounds designed to inhibit the enzyme that controls repressive histone modification.
“When we gave the AD animals this enzyme inhibitor, we saw the rescue of cognitive function confirmed through evaluations of recognition memory, spatial memory and working memory. We were quite surprised to see such dramatic cognitive improvement,” Yan said.
“At the same time, we saw the recovery of glutamate receptor expression and function in the frontal cortex.”
The improvements lasted for one week; future studies will focus on developing compounds that penetrate the brain more effectively and are thus longer-lasting.
Brain disorders, such as AD, are often polygenetic diseases, Yan explained, where many genes are involved and each gene has a modest impact. An epigenetic approach is advantageous, she said, because epigenetic processes control not just one gene but many genes.
“An epigenetic approach can correct a network of genes, which will collectively restore cells to their normal state and restore the complex brain function,” she explained.
“We have provided evidence showing that abnormal epigenetic regulation of glutamate receptor expression and function did contribute to cognitive decline in Alzheimer’s disease,” Yan concluded. “If many of the dysregulated genes in AD are normalized by targeting specific epigenetic enzymes, it will be possible to restore cognitive function and behavior.”
The Latest on: Epigenetics
via Google News
The Latest on: Epigenetics
- Epigenetics Applications Market New Applications, Top Players, Regional Outlook and Business Opportunities 2022on November 20, 2020 at 1:55 pm
Kenneth Research has released a report on Epigenetics Market which is anticipated to grow significantly over the ...
- After more than a decade, ChIP-seq may be quantitative after allon November 20, 2020 at 1:42 pm
For more than a decade, scientists studying epigenetics have used a powerful method called ChIP-seq to map changes in proteins and other critical regulatory factors across the genome. While ChIP ...
- Solving a mystery: How the TB bacterium develops rapid resistance to antibioticson November 19, 2020 at 12:35 pm
These slow growing bacteria have long puzzled TB researchers with their fairly rapid resistance to antibiotics. Researchers may have been barking up the wrong tree in exploring genetics, because the ...
- Solving a mystery: How the TB bacterium develops rapid resistance to antibioticson November 18, 2020 at 4:00 pm
Their discovery could help advance new diagnostics, therapeutics and vaccine targets. Epigenetics is the study of inheritable changes in gene expression that do not involve a corresponding change ...
- Epigenetics Applications Market Development, News and significant Growth With Regional Trends By Forecast 2022on November 17, 2020 at 5:45 am
Kenneth Research has released a report on Epigenetics Applications Market which is anticipated to grow significantly ...
- Epigenetics Market to Garner $2.16 Bn, Globally, by 2027 at 13.6% CAGR, Says Allied Market Researchon November 17, 2020 at 3:25 am
Technological advancements, rise in prevalence of cancer, and increase in genome mapping programs and number of R&D activities drive the growth of the global epigenetics market. However ...
- Evotec and Storm Therapeutics Leverage Indigo Platform to Progress Oncology Project Towards Clinical Studieson November 16, 2020 at 11:01 pm
STORM WILL PROGRESS THE COMPOUND TOWARDS THE CLINIC USING INDIGO, EVOTEC’S INTEGRATED IND-ENABLING PLATFORM HAMBURG, GERMANY / ACCESSWIRE / November 17, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT ...
- Epigenetics Market to Garner $2.16 Bn, Globally, by 2027 at 13.6% CAGR, Says Allied Market Researchon November 16, 2020 at 8:58 pm
Nov. 16, 2020 /PRNewswire/ -- Allied Market Research recently published a report, titled, "Epigenetics Market by Product (Kits, Reagents, Enzymes, and Instruments), Application (Oncology and Non ...
- How Epigenetics Could Turn Things Around For Alzheimer’s Diseaseon November 10, 2020 at 6:04 am
Some researchers are working a different angle, called epigenetics, to try to find a way to stop the disease. Genetics considers a person’s DNA sequence, and epigenetics looks at how the cell ...
via Bing News